Showing 6831-6840 of 8847 results for "".
- Concerto Biosciences Completes Data Collection for Massive Skin Microbiome Interaction Projecthttps://practicaldermatology.com/news/concerto-biosciences-completes-data-collection-for-massive-skin-microbiome-interaction-project/2474768/Concerto Biosciences announced today that it has concluded the data acquisition phase of the Skin Universe Project (SUP), collecting over 33 million empirical data points in what it calls the largest known dataset of skin microbial interactions.
- Socioeconomic Disparities Tied to HS Diagnoseshttps://practicaldermatology.com/news/socioeconomic-disparities-tied-to-hs-diagnoses/2474703/Patients living in lower socioeconomic neighborhoods are more likely to be diagnosed with hidradenitis suppurativa (HS), according to a new cross-sectional analysis of data from the University of California San Francisco (UCSF) health system.
- GW Prior Certification Coordinator Offers Tips at ElderDermhttps://practicaldermatology.com/news/GW-Prior-Certification-Coordinator-Offers-Tips-ElderDerm/2474666/There are no shortcuts to getting dermatologic treatments authorized by Medicaid and insurance companies, George Washington University Department of Dermatology’s prior certification coordinator said at the ElderDerm 2025 Conference in Washington, DC. Effort and diligence are the keys when
- Dermeleve to Modify Program for Sampleshttps://practicaldermatology.com/news/Dermeleve-Modify-Program-Samples/2474651/Dermeleve will transition away from its auto-ship model and self-serve request program for samples, but will still offer samples directly to patients and to clinicians who choose to hole wholesale inventory, the company said in an email to partners. “To ensure your patients can still ‘try
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
- Dupilumab Improves Clinical and Immunologic Markers in NShttps://practicaldermatology.com/news/dupilumab-improves-clinical-and-immunologic-markers-in-ns/2474591/Results from a recent pilot study suggest an IL-4/IL-13 blockade with dupilumab significantly improved skin and immunologic abnormalities in patients with Netherton syndrome (NS).
- SEEN Expands Pediatric Line with Fragrance-Free Baby Shampoo and Body Washhttps://practicaldermatology.com/news/seen-expands-pediatric-line-with-fragrance-free-baby-shampoo-and-body-wash/2474436/SEEN has announced the launch of SEEN Baby 2-in-1 Fragrance Free, a new ultra-gentle shampoo and body wash designed specifically for infants and young children with sensitive or eczema-prone skin, according to a news release from the manufacturer.
- FDA Gives Nod to First Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fda-gives-nod-to-first-cell-based-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2474382/The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (prademagene zamikeracel, pz-cel), making it the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The approval addresses a major unmet clinical nee
- RILECSU Study: Rilzabrutinib Effective for Symptoms in Hard-to-Treat Urticariahttps://practicaldermatology.com/news/rilecsu-trial-rilzabrutinib-eases-symptoms-in-hard-to-treat-urticaria/2474350/Rilzabrutinib significantly reduced itch and hives in adults with antihistamine-refractory chronic spontaneous urticaria (CSU), according to new phase 2 trial results published in JAMA Dermatology.
- Study: Laser Therapy Shows Success in HS Management for Skin of Colorhttps://practicaldermatology.com/news/new-study-highlights-laser-therapy-success-in-hs-management-for-skin-of-color/2474344/Fractional ablative CO₂ laser therapy (AFCL) significantly improved hidradenitis suppurativa (HS) outcomes among patients with skin of color, according to a new retrospective study presented at the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual